Descartes-08, an investigational CAR T-cell therapy for generalized myasthenia gravis (gMG), markedly reduced disease activity among patients who completed the entire protocol of a three-month Phase 2b clinical trial. The treatment was also associated with reduced levels of MG-driving self-reactive antibodies, but not in the broader antibody…
More than half of adults with generalized myasthenia gravis (gMG) show a clinically meaningful response to Ultomiris (ravulizumab-cwvz) within about two weeks of a first dose, according to a post-hoc analysis of clinical trial data. In contrast, more than 80% of these 139 trial patients experienced a meaningful…
A Phase 1 clinical trial for IGM-2644, a potential first-in-class immune T-cell engager therapy for generalized myasthenia gravis (gMG), should begin by the end of the year, said its developer IGM Biosciences. “Our early pivot to using T-cell engagers in autoimmune disease has enabled significant progress on these…
Amgen’s antibody-based therapy inebilizumab reduces the severity of generalized myasthenia gravis (MG), according to top-line data from a Phase 3 clinical trial. Dubbed MINT (NCT04524273), the study showed inebilizumab’s therapeutic efficacy in gMG patients who test positive for self-reactive antibodies against the acetylcholine receptor (AChR) or muscle-specific…
Both Soliris (eculizumab) and Vyvgart (efgartigimod alfa-fcab) rapidly eased disease severity among adults with generalized myasthenia gravis (gMG), according to a real-world study that compared the two therapies. Soliris outperformed Vyvgart in its ability to reduce gMG severity and corticosteroid dose over a year of treatment, however.
Using a combination of two standardized assessment tools may be better than the classification process now in place in predicting the outcomes of people with a thymoma, or thymus tumor, associated with myasthenia gravis (MG), a new study suggests. The newly proposed system, from researchers in China, would classify…
The anti-malaria drug dihydroartemisinin, known simply as DHA, showed promise in a rat model of myasthenia gravis (MG) as a potential treatment for the autoimmune disease, a new study reports. In addition to alleviating many MG-related symptoms, DHA inhibited pro-inflammatory T-cells while boosting immune-suppressing T-regulatory cells. Treatment with the…
People with myasthenia gravis (MG) who have more active disease are at a higher risk of having an exacerbation, or a sudden worsening of symptoms, a new study from Germany has found. Even after appropriate treatment for an exacerbation, this group of MG patients remained clinically more impaired, the…
Nearly six months of treatment with RemeGen’s telitacicept (RC18) lessened disease activity in adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor, according to data from a Phase 2 clinical trial in China. “Telitacicept demonstrated safety [and] good tolerability and reduced clinical…
Patients, especially women, experience a high degree of side effects from myasthenia gravis (MG) treatment, according to a U.K. survey examining real-world use of the medications. As steroid-sparing agents, mycophenolate mofetil (sold as CellCept) and methotrexate (sold as Trexall, among others) were less likely to be discontinued…
Get regular updates to your inbox.
